You're three demos deep into the search for an imaging platform, and the one from QMENTA is the one that stuck. The AI orchestration is genuinely impressive: models version-locked from baseline to closeout, an audit trail that seems to write itself. For a moment, the search feels over.
Then you look back at your protocol. Your trial isn't a CNS program at all. It's a multi-site mammography trial, a dozen countries, and a reader pool that needs BI-RADS-trained radiologists on hand rather than neuro specialists. So you open a new tab and type the search that brought you here: QMENTA alternative.
You're not the first clinical operations lead to run that search, and QMENTA and Collective Minds Research are usually the two names that surface. QMENTA has built a strong reputation as a governed platform for regulated neuroimaging trials, with deep AI and biomarker tooling built into the workflow. Collective Minds Research takes a different approach: network-first, connecting sites, sponsors, and specialist readers across modalities like mammography, rheumatology, musculoskeletal, and brain and CNS, with growing capabilities in prostate and vascular imaging. Mammography in particular is a modality few imaging-trial platforms treat as a specialty in its own right; most fold it into a broader oncology offering. This article walks through both platforms across the capabilities that matter most in an imaging-heavy trial, from data intake through central review, AI, and compliance, so you can see where each one fits, and where a QMENTA alternative might serve your program better.
Both platforms are purpose-built for imaging in clinical research, and both are used by sponsors, CROs, and imaging core labs. Where they diverge is in focus: QMENTA concentrates on regulated, AI-heavy neuroimaging trials, with oncology and cardiac as secondary areas, in a single governed system from ingestion to submission. Collective Minds Research is built for speed and reach across mammography, rheumatology, MSK, and brain and CNS trials, with growing prostate and vascular imaging capabilities, backed by a large pre-connected site network and specialist readers by modality.
| Feature | QMENTA | Collective Minds Research |
| Primary Focus | Governed, AI-driven neuroimaging trials, with oncology and cardiac as secondary areas, from site activation to regulatory submission. | Fast, connected imaging trials across mammography, rheumatology, MSK, and brain/CNS, with growing prostate and vascular imaging capabilities. |
| Data Intake | Drag-and-drop upload or direct PACS connector, with PHI removed at ingestion. Vendor-neutral across major scanner manufacturers. | Connect edge gateway, integrated directly with site modalities and PACS, de-identified and pseudonymized at source, across a network of 300+ pre-connected sites. |
| Central Review | Zero-footprint browser viewer, dedicated radiologist worklists, structured double-read and adjudication, with the sponsor's own readers or QMENTA's expert network. | Specialist readers matched by modality from a network of 30,000+ imaging experts, with real-time pipeline visibility from scanner to reader lock. |
| AI & Biomarkers | 50+ validated imaging AI workflows, version-locked and reproducible, with support for bring-your-own algorithms. | Integrations with third-party AI partners, plus a professional-grade viewer for image analysis and annotation. |
| Study Management | Role-based projects, including a multi-site model where each site sees only its own data. Fully custom roles, such as a Site PI, are set up with QMENTA support. Query management, imaging EDC, e-signatures with approval workflows, scanner harmonization, and automated closeout documentation. | Shared libraries of sites, roles, and forms across projects. Self-configured roles with site, project, or repository scope and permissions down to the event. Personal task lists, per-event notifications by role, eCRFs with signed approvals, and a full audit log. |
| Compliance | 510(k)-cleared, FDA 21 CFR Part 11, HIPAA, GDPR, and GxP, with zero nonconformities across external pharma audits. | 21 CFR Part 11, GxP/GCP, ALCOA+, GDPR, ISO 27001, and HIPAA-aligned under a validated Quality Management System, available via AWS Marketplace. |
| Ideal Use Case | CNS and neuro-focused regulated trials that need built-in AI biomarker tooling and audit-ready closeout. | Mammography, rheumatology, MSK, and brain/CNS trials, plus emerging prostate and vascular imaging programs, that need fast site activation and specialist readers by modality. |
You might also like to read: clinical trial imaging platforms
Both platforms cover the same broad territory, from the first scan to the submission package, but they get there differently. The sections below walk through the five areas that most often decide which platform fits a given imaging program.
QMENTA supports cloud-based upload from any site or scanner, either through drag-and-drop for coordinators or a direct PACS connector, and it is vendor-neutral across GE Healthcare, Siemens Healthineers, Philips, Canon, and United Imaging systems. PHI is removed automatically at the point of ingestion, before data enters the platform, and automated image and protocol QC flags deviations within minutes of upload rather than weeks later at central review.
Collective Minds Research approaches the same problem through its Connect technology, which integrates directly with a site's PACS or modality and de-identifies and pseudonymizes data at source, inside the hospital, before anything is shared. Data then streams to the central platform as soon as it is acquired, with no manual exports and less compliance friction for the site. Because more than 300 sites are already equipped with the Connect gateway, many studies can begin centralized imaging data management without the technical and contractual setup that usually delays a trial's first scan. Central reviewers can typically begin quality control almost as soon as an image is acquired, rather than waiting for a batch upload to complete.
QMENTA's central review runs through a zero-footprint browser viewer with roughly one-second load times, dedicated radiologist worklists, and structured double-read and adjudication workflows, with role-based access so sites, sponsors, CROs, and radiologists each see only what they need. Reads can be done by the sponsor's own readers or through QMENTA's network of expert radiologists. This structure is built for the demands of an imaging core lab running standardized, high-volume reads.
Collective Minds Research also supports configurable reads, double reads, and adjudication, and the difference is in who does the reading. The platform draws on a network of more than 30,000 imaging experts across 300+ institutions, so a study can be staffed with specialists by modality: BI-RADS-trained radiologists for mammography, musculoskeletal and rheumatology readers for joint and spine endpoints, neuroradiologists for brain and CNS. On top of that staffing pool, real-time pipeline visibility tracks each image's status from the moment it leaves the scanner to the moment it is locked by the reader, so sponsors and core labs aren't waiting on a batch report to know where a case stands. That combination makes it easier to staff a subspecialty read or scale reader capacity quickly when a study's needs shift.
In a multi-site imaging trial, study management comes down to three questions: who can see which data, who can do what with it, and who is waiting on whom. Both platforms answer them, but with different building blocks.
QMENTA organizes access around project types. Its standard projects use five roles (Owner, Project Admin, Data Admin, Collaborator, and Guest), while its Star project model is built for multi-site studies: each site sees only its own data, project-level roles see everything, and groups separate access by site. Teams that need something more specific, such as a Site PI limited to one site or a Diagnostic Adjudicator who reads across all sites, can define their own roles in a custom project, although project types beyond the standard one are set up through QMENTA support rather than self-service. Around that sit a query management system, an imaging EDC, electronic signatures with approval workflows, and a log of every change to user rights. Its harmonization layer aligns scanner protocols and data structures across vendors before data reaches a reviewer, protocol deviations trigger a site-level notification within minutes, and closeout documentation is generated from the running audit trail. As far as its public documentation shows, personal task lists and user-configurable notifications beyond those deviation alerts are not part of the picture.
Collective Minds Research builds study management around the repository, a container that holds a shared library of sites, roles, forms, and tools used by every project inside it. Each site is registered once, with its own global ID, a description, and a restricted Site Info tab that only repository-level members can open, and a site has to exist in the library before it can be attached to a project. Subjects are then affiliated with those sites, and that affiliation is what drives access.
Roles are not a fixed list. A role is assembled from permissions and a data scope (site, project, or repository), so a study team can model its own organization: a coordinator limited to a single site, a reader who only runs and signs the events assigned to them, a project manager with a project-wide view, a data manager who edits forms. Permissions reach down to the pipeline, individual events, subjects, results, and reports. A site-scoped member sees and adds subjects only for their own site, while a project-scoped member sees all subjects and can assign them to any site. Approval is separated from editing: moving a pipeline from design to live, signing off a form, or approving a change in access takes an explicit approve permission, and nobody can approve access assigned to or by themselves.
The same role model drives the day-to-day work. Every member gets a personal task list built from the events assigned to their roles, and when someone works across several projects, those tasks appear in a single list. Notifications follow the same logic: administrators choose which roles are notified for each event, including when a QC event is approved or rejected, delivery goes through the web app, email, or both, and individual users can opt out per project and per event. Every action on data and every change to the project structure is recorded in an audit log.
The practical difference is where the configuration lives. QMENTA offers proven project models and a strong query, EDC, and closeout toolkit, with deeper customization routed through its team. Collective Minds Research puts site, role, and task configuration in the hands of the study team, which matters most when many parties, such as sites, readers, CRO staff, and sponsors, each need a different view of the data and a different set of actions. Study stages and events can be duplicated in one click to set up multi-reader and multi-site studies, and customized eCRFs with enforced subject ID formats sit alongside imaging inside a broader medical imaging workflow.
Introduction to Collective Minds Research for CROs and Pharma.
AI is where QMENTA's neuro focus shows most clearly. The platform gives teams a governed environment to deploy, run, and scale validated AI algorithms, whether they are QMENTA's own, a sponsor's, or a third party's, with more than 50 validated imaging AI workflows and biomarker tools available out of the box. Every model is version-locked and reproducible, so the same algorithm applied at baseline is applied at every later timepoint, a detail regulators scrutinize closely in longitudinal imaging biomarkers.
Collective Minds Research supports image analysis through a medical-grade DICOM viewer with MPR, MIP, 3D rendering, segmentation, and annotation tools, and partnerships with third-party AI providers, such as contextflow, for tasks like segmentation and quantification. This brain imaging in clinical trials use case, and other imaging-heavy indications, benefit from being able to bring in specialized AI tools as a study's analysis needs evolve, rather than working only within one vendor's model library. If a built-in library of validated biomarkers is the deciding factor for your endpoint, QMENTA is the stronger fit on this point.
QMENTA positions its compliance stack as built in rather than bolted on: a 510(k)-cleared platform, FDA 21 CFR Part 11, HIPAA, GDPR, and GxP, deployable on GCP, AWS, or Azure depending on a sponsor's security requirements, and fully independent of any pharmaceutical company investment. QMENTA also reports zero nonconformities across external pharmaceutical partner audits to date, alongside a production footprint of more than 250 imaging sites and over 16 million images processed across more than 1.3 million subjects.
Collective Minds Research operates under a validated Quality Management System aligned with 21 CFR Part 11, GxP/GCP, ALCOA+, GAMP, GDPR, ISO 27001, and HIPAA, hosted on AWS in Frankfurt with multi-zone redundancy, and is built on a single, unified cloud codebase rather than a stack assembled through acquisitions. That architecture supports a pre-connected network of 300+ sites and 30,000+ imaging experts, backed by more than 450 research projects with academic medical centers such as Karolinska Institutet, KU Leuven, and the Medical University of Vienna. It is designed to scale a study up or down without the integration overhead of stitching together legacy systems. The platform is also available through the AWS Marketplace, which simplifies deployment and invoicing for sponsors already standardized on AWS.
There is no universally "better" platform between the two. The right choice depends on your therapeutic area, how deep the reader bench needs to be in your modality, and how much weight your protocol places on built-in AI biomarker tooling versus flexibility to bring in outside models.
Whichever platform you are evaluating, the same operational questions determine whether it will hold up once the trial is underway:
Back to that second tab. QMENTA earned its reputation fairly: for a governed, CNS-focused system with deep AI biomarker tooling built in, it's a strong, credible choice. But not every imaging trial is a neuroimaging trial, and the readers who matter most are the ones trained in your modality.
Collective Minds Research gives study teams a faster path to site activation through a pre-connected network, de-identification at source through Connect, direct access to a global network of more than 30,000 imaging experts for modality-specific reads, and a single platform that combines imaging, eCRFs, and digital signatures without the integration debt of a suite built through acquisitions. If your next imaging trial sits in mammography, rheumatology, MSK, or brain and CNS, or you're expanding into prostate or vascular imaging, it is worth putting Collective Minds Research on your shortlist alongside QMENTA.
Do you want to learn more about our imaging solutions?
Get in touch here to book a demo with one of our specialists.
For CNS and neuro-focused trials that rely heavily on QMENTA's built-in AI biomarker tooling, it can be a close replacement. For imaging trials in mammography, rheumatology, or MSK, or for sponsors who want specialist readers matched to their modality and de-identification at source, Collective Minds Research is often a better fit than a like-for-like swap.
Yes. The platform is built around a pre-connected network of more than 300 imaging sites, direct PACS and modality integration through Connect, and real-time visibility into every site's imaging status, which supports coordinating imaging endpoints across large, multi-site, multi-country trials.
Both platforms are designed to sit alongside a sponsor's broader clinical trial stack rather than replace it. QMENTA is deployable on GCP, AWS, or Azure depending on a sponsor's procurement requirements, while Collective Minds Research is available through the AWS Marketplace and includes its own eCRFs and digital signatures, which can reduce the need for separate reconciliation with an external EDC.
Focus on how images move from the site into the platform, how quickly protocol or quality issues surface, how central review and adjudication are structured, whether AI and biomarker tooling is built in or added separately, and how the platform's compliance and audit trail hold up under regulatory scrutiny. The clinical trial imaging platforms comparison walks through these criteria in more detail across a wider set of vendors.
Reviewed by Pär Kragsterman on October 13, 2026